Findings

What do systematic reviews say?

62 questions · 63 findings · 8 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 13 · 20.6%GRADE not reported 1 · 1.6%Very low 13 · 20.6%Low 28 · 44.4%Moderate 8 · 12.7%High 0 · 0%

Macrolides vs placebo

All‐cause mortality · adults with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 540 participants
Low

Macrolides vs placebo

Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · adults with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Moderate

Macrolides vs placebo

Quality of life: change · adults with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 305 participants
Low

Macrolides vs no intervention

Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults with bronchiectasis

Macrolides showed no clear difference in ≥ 1 exacerbation compared with no intervention (moderate certainty).

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
OR 0.31 [0.08, 1.15]
1 study · 43 participants
Moderate

Macrolides vs no intervention

Hospitalisation ‐ not reported · adults with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolides vs no intervention

Serious adverse events ‐ not reported · adults with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)

Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID

It is very uncertain whether regimens containing macrolides (azithromycin) changes clinical cure according to criteria established by study authors… compared with regimens containing tetracycline (doxycycline) (very low certainty).

2 findings from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
RR 1.18 [0.89, 1.55]
Studies not reported
Very low
Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
RR 1.35 [1.1, 1.67]
Studies not reported
Moderate

Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)

Clinical cure according to criteria established by study authors Severe PID · women with PID

Regimens containing macrolides (azithromycin) showed no clear difference in clinical cure according to criteria established by study authors… compared with regimens containing tetracycline (doxycycline) (low certainty).

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
RR 1 [0.96, 1.05]
Studies not reported
Low

Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)

Adverse events: any antibiotic‐related adverse event leading to discontinuation of therapy · women with PID

Regimens containing macrolides (azithromycin) showed no clear difference in adverse events: any antibiotic‐related adverse event leading to… compared with regimens containing tetracycline (doxycycline) (low certainty).

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
RR 0.71 [0.38, 1.34]
Studies not reported
Low

Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)

Microbiological clearance · women with PID

Regimens containing macrolides (azithromycin) showed no clear difference in microbiological clearance compared with regimens containing tetracycline (doxycycline); GRADE not reported.

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
RR 1.02 [0.98, 1.06]
Studies not reported
GRADE not reported

Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)

Laparoscopic evidence of resolution of PID based on physician opinion · women with PID

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)

Length of stay · women with PID

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)

Fertility outcome · women with PID

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for pelvic inflammatory disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fluoroquinolones vs macrolides

Diarrhoea · patients with Shigella dysentery

It is very uncertain whether fluoroquinolones changes diarrhoea on compared with macrolides (very low certainty).

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
RR 0.6 [0.24, 1.49]
2 studies · 189 participants
Very low

Fluoroquinolones vs macrolides

Relapse ‐ not reported · patients with Shigella dysentery

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fluoroquinolones vs macrolides

Serious adverse events ‐ not reported · patients with Shigella dysentery

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fluoroquinolones vs macrolides

Other adverse events clinical criteria · patients with Shigella dysentery

It is very uncertain whether fluoroquinolones changes other adverse events clinical criteria compared with macrolides (very low certainty).

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
RR 1.33 [0.32, 5.56]
1 study · 76 participants
Very low

Erythromycin vs any other macrolide

Clinical cure: syndromic approach · sexually active adults

Macrolide (erythromycin) showed no clear difference in clinical cure: syndromic approach compared with any other macrolide (low certainty).

1 finding from 1 review

Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults 2017 · Cochrane Headline outcomes only
RR 1 [0.91, 1.1]
2 studies · 269 participants
Low

Erythromycin vs any other macrolide

Clinical cure: aetiological approach · sexually active adults

Macrolide (erythromycin) showed no clear difference in clinical cure: aetiological approach compared with any other macrolide (low certainty).

1 finding from 1 review

Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults 2017 · Cochrane Headline outcomes only
RR 1.04 [0.93, 1.16]
2 studies · 211 participants
Low

Erythromycin vs any other macrolide

Minor adverse events · sexually active adults

It is very uncertain whether macrolide (erythromycin) changes minor adverse events compared with any other macrolide (very low certainty).

1 finding from 1 review

Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults 2017 · Cochrane Headline outcomes only
RR 1.14 [0.63, 2.06]
1 study · 101 participants
Very low